Zetia

Sanofi and Regeneron's cholesterol antibody aces phase III trial

comparator drug Zetia (ezetimibe) from Merck &Co.

Merck profit slides as generics continue to bite

HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe) ... and Vytorin (ezetimibe and

Merck & Co wins green light in US for Zetia-Lipitor combo

Vytorin extension wins FDA approval. Merck &Co has been awarded marketing approval for Liptruzet, a new combination cholesterol treatment based on Zetia and generic atorvastatin. ... Sales of Zetia as a monotherapy reached $2.57bn last year, with Vytorin

Merck & Co's sugammadex delayed in US

insomnia drug suvorexant, ovarian cancer treatment vintafolide, and its combination of Zetia (ezetimibe) and atorvastatin for high cholesterol.

Merck forges on with Vytorin trial after safety review

The debate has dampened demand for Vytorin and also ezetimibe monotherapy Zetia, which has had its own problems including a study which suggested the drug increased atherosclerotic plaque volumes in peripheral

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]